Evans CP - Search Results

1

The Immunotherapy and Immunosuppressive Signaling in Therapy-Resistant Prostate Cancer.

Xu P, Wasielewski LJ, Yang JC, Cai D, Evans CP, Murphy WJ, Liu C. Xu P, et al. Among authors: evans cp. Biomedicines. 2022 Jul 22;10(8):1778. doi: 10.3390/biomedicines10081778. Biomedicines. 2022. PMID: 35892678 Free PMC article. Review.

2

Interleukin-8 confers androgen-independent growth and migration of LNCaP: differential effects of tyrosine kinases Src and FAK.

Lee LF, Louie MC, Desai SJ, Yang J, Chen HW, Evans CP, Kung HJ. Lee LF, et al. Among authors: evans cp. Oncogene. 2004 Mar 18;23(12):2197-205. doi: 10.1038/sj.onc.1207344. Oncogene. 2004. PMID: 14767470

3

Biologic agents as adjunctive therapy for prostate cancer: a rationale for use with androgen deprivation.

Nelson EC, Cambio AJ, Yang JC, Lara PN Jr, Evans CP. Nelson EC, et al. Among authors: evans cp. Nat Clin Pract Urol. 2007 Feb;4(2):82-94. doi: 10.1038/ncpuro0700. Nat Clin Pract Urol. 2007. PMID: 17287869 Review.

4

CRM1 blockade by selective inhibitors of nuclear export attenuates kidney cancer growth.

Inoue H, Kauffman M, Shacham S, Landesman Y, Yang J, Evans CP, Weiss RH. Inoue H, et al. Among authors: evans cp. J Urol. 2013 Jun;189(6):2317-26. doi: 10.1016/j.juro.2012.10.018. Epub 2012 Oct 16. J Urol. 2013. PMID: 23079374 Free PMC article.

5

NF-κB2/p52 induces resistance to enzalutamide in prostate cancer: role of androgen receptor and its variants.

Nadiminty N, Tummala R, Liu C, Yang J, Lou W, Evans CP, Gao AC. Nadiminty N, et al. Among authors: evans cp. Mol Cancer Ther. 2013 Aug;12(8):1629-37. doi: 10.1158/1535-7163.MCT-13-0027. Epub 2013 May 22. Mol Cancer Ther. 2013. PMID: 23699654 Free PMC article.

6

Inhibition of ABCB1 expression overcomes acquired docetaxel resistance in prostate cancer.

Zhu Y, Liu C, Nadiminty N, Lou W, Tummala R, Evans CP, Gao AC. Zhu Y, et al. Among authors: evans cp. Mol Cancer Ther. 2013 Sep;12(9):1829-36. doi: 10.1158/1535-7163.MCT-13-0208. Epub 2013 Jul 16. Mol Cancer Ther. 2013. PMID: 23861346 Free PMC article.

7

lncRNA-dependent mechanisms of androgen-receptor-regulated gene activation programs.

Yang L, Lin C, Jin C, Yang JC, Tanasa B, Li W, Merkurjev D, Ohgi KA, Meng D, Zhang J, Evans CP, Rosenfeld MG. Yang L, et al. Among authors: evans cp. Nature. 2013 Aug 29;500(7464):598-602. doi: 10.1038/nature12451. Epub 2013 Aug 14. Nature. 2013. PMID: 23945587 Free PMC article.

8

CTA095, a novel Etk and Src dual inhibitor, induces apoptosis in prostate cancer cells and overcomes resistance to Src inhibitors.

Guo W, Liu R, Bhardwaj G, Ma AH, Changou C, Yang JC, Li Y, Feng C, Luo Y, Mazloom A, Sanchez E, Wang Y, Huang W, Patterson R, Evans CP, Lam KS, Kung HJ. Guo W, et al. Among authors: evans cp. PLoS One. 2013 Aug 15;8(8):e70910. doi: 10.1371/journal.pone.0070910. eCollection 2013. PLoS One. 2013. PMID: 23967135 Free PMC article.

9

Inhibition of constitutively active Stat3 reverses enzalutamide resistance in LNCaP derivative prostate cancer cells.

Liu C, Zhu Y, Lou W, Cui Y, Evans CP, Gao AC. Liu C, et al. Among authors: evans cp. Prostate. 2014 Feb;74(2):201-9. doi: 10.1002/pros.22741. Epub 2013 Oct 16. Prostate. 2014. PMID: 24307657 Free PMC article.

10

Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer.

Liu C, Lou W, Zhu Y, Nadiminty N, Schwartz CT, Evans CP, Gao AC. Liu C, et al. Among authors: evans cp. Clin Cancer Res. 2014 Jun 15;20(12):3198-3210. doi: 10.1158/1078-0432.CCR-13-3296. Epub 2014 Apr 16. Clin Cancer Res. 2014. PMID: 24740322 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

240 results

Search Page